$WGS
GeneDx Holdings Corp.

2023 Q4 Form 10-Q Financial Statement

#000181833123000068 Filed on November 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $57.42M $53.30M
YoY Change -6.41% -35.96%
Cost Of Revenue $26.66M $28.04M
YoY Change -65.67% -59.76%
Gross Profit $30.75M $25.26M
YoY Change -288.33% 86.43%
Gross Profit Margin 53.56% 47.39%
Selling, General & Admin $37.93M $42.86M
YoY Change -44.83% -52.01%
% of Gross Profit 123.34% 169.69%
Research & Development $11.33M $14.29M
YoY Change -25.57% 6.99%
% of Gross Profit 36.84% 56.57%
Depreciation & Amortization $6.094M $5.166M
YoY Change -82.1% -26.15%
% of Gross Profit 19.82% 20.45%
Operating Expenses $56.40M $57.15M
YoY Change -81.72% -44.34%
Operating Profit -$25.64M -$42.97M
YoY Change -92.11% -52.69%
Interest Expense -$492.0K $1.640M
YoY Change -103.04% 103.47%
% of Operating Profit
Other Income/Expense, Net -$49.00K $509.0K
YoY Change -96.14%
Pretax Income -$26.18M -$42.46M
YoY Change -91.52% -45.32%
Income Tax -$411.0K -$172.0K
% Of Pretax Income
Net Earnings -$25.77M -$42.29M
YoY Change -91.65% -45.49%
Net Earnings / Revenue -44.89% -79.33%
Basic Earnings Per Share -$1.64
Diluted Earnings Per Share -$0.99 -$1.64
COMMON SHARES
Basic Shares Outstanding 25.88M shares 25.77M shares
Diluted Shares Outstanding 25.79M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $130.1M $114.3M
YoY Change 5.04% -40.27%
Cash & Equivalents $99.68M $87.39M
Short-Term Investments $30.47M $26.90M
Other Short-Term Assets $10.60M $5.024M
YoY Change 65.85% -48.2%
Inventory $8.777M $9.349M
Prepaid Expenses $8.640M $10.74M
Receivables $32.37M $31.90M
Other Receivables $445.0K $500.0K
Total Short-Term Assets $182.3M $171.8M
YoY Change -14.24% -43.96%
LONG-TERM ASSETS
Property, Plant & Equipment $32.48M $35.75M
YoY Change -36.97% -57.63%
Goodwill
YoY Change
Intangibles $172.6M $176.1M
YoY Change -7.51% -7.38%
Long-Term Investments
YoY Change
Other Assets $4.413M $6.059M
YoY Change -31.95% -23.96%
Total Long-Term Assets $236.4M $245.5M
YoY Change -15.06% -53.01%
TOTAL ASSETS
Total Short-Term Assets $182.3M $171.8M
Total Long-Term Assets $236.4M $245.5M
Total Assets $418.8M $417.3M
YoY Change -14.7% -49.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.24M $15.37M
YoY Change -77.75% -61.68%
Accrued Expenses $12.15M $13.32M
YoY Change -68.72% -49.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $497.0K $198.0K
YoY Change -89.54% -43.27%
Total Short-Term Liabilities $58.82M $68.37M
YoY Change -59.24% -57.88%
LONG-TERM LIABILITIES
Long-Term Debt $52.69M $6.052M
YoY Change 743.01% -43.18%
Other Long-Term Liabilities $14.74M $22.66M
YoY Change -33.02% 12.18%
Total Long-Term Liabilities $67.42M $28.71M
YoY Change 138.67% -6.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $58.82M $68.37M
Total Long-Term Liabilities $67.42M $28.71M
Total Liabilities $190.7M $163.0M
YoY Change -19.6% -39.1%
SHAREHOLDERS EQUITY
Retained Earnings -$1.300B -$1.274B
YoY Change 15.63% 56.24%
Common Stock $2.000K $2.000K
YoY Change -94.74% -94.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $228.0M $254.3M
YoY Change
Total Liabilities & Shareholders Equity $418.8M $417.3M
YoY Change -14.7% -49.66%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$25.77M -$42.29M
YoY Change -91.65% -45.49%
Depreciation, Depletion And Amortization $6.094M $5.166M
YoY Change -82.1% -26.15%
Cash From Operating Activities -$29.86M -$41.23M
YoY Change -53.82% -53.34%
INVESTING ACTIVITIES
Capital Expenditures $2.376M $120.0K
YoY Change -16.34% -102.81%
Acquisitions
YoY Change
Other Investing Activities -$2.488M -$27.02M
YoY Change
Cash From Investing Activities -$4.864M -$27.13M
YoY Change 71.27% 534.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 47.10M -910.0K
YoY Change 67190.0% 40.65%
NET CHANGE
Cash From Operating Activities -29.86M -41.23M
Cash From Investing Activities -4.864M -27.13M
Cash From Financing Activities 47.10M -910.0K
Net Change In Cash 12.38M -69.27M
YoY Change -118.36% -25.75%
FREE CASH FLOW
Cash From Operating Activities -$29.86M -$41.23M
Capital Expenditures $2.376M $120.0K
Free Cash Flow -$32.23M -$41.35M
YoY Change -52.25% -50.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.03
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.03
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11773065 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11773065 shares
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
254258000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
253705000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
417285000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
490942000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
53303000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
83234000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
28044000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
69685000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
25259000 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
13549000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14288000 usd
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
34383000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26099000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
54931000 usd
CY2023Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
8282000 usd
CY2022Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
CY2023Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-2794000 usd
CY2022Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-1697000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-42967000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-90816000 usd
CY2023Q3 wgs Change In Fair Market Value Of Warrant And Earn Out Contingent Liabilities
ChangeInFairMarketValueOfWarrantAndEarnOutContingentLiabilities
590000 usd
CY2022Q3 wgs Change In Fair Market Value Of Warrant And Earn Out Contingent Liabilities
ChangeInFairMarketValueOfWarrantAndEarnOutContingentLiabilities
12978000 usd
wgs Change In Fair Market Value Of Warrant And Earn Out Contingent Liabilities
ChangeInFairMarketValueOfWarrantAndEarnOutContingentLiabilities
684000 usd
wgs Change In Fair Market Value Of Warrant And Earn Out Contingent Liabilities
ChangeInFairMarketValueOfWarrantAndEarnOutContingentLiabilities
54350000 usd
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1053000 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
190000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2092000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-999000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1134000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
509000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13170000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-42458000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-77646000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-172000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-65000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-42286000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-77581000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-240219000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
296113000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-42286000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
431000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
253705000 usd
us-gaap Net Income Loss
NetIncomeLoss
-149994000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
266000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
586000 usd
wgs Stock Issued During Period Value Stock Splits
StockIssuedDuringPeriodValueStockSplits
6692000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
254258000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
637274000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-77581000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
329000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1272000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
388103000 usd
us-gaap Net Income Loss
NetIncomeLoss
-240219000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2198000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
41553000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
197659000 usd
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
172000000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
561294000 usd
us-gaap Net Income Loss
NetIncomeLoss
-149994000 usd
us-gaap Net Income Loss
NetIncomeLoss
-240219000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
27640000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
25269000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
10402000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
2954000 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
586000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
41553000 usd
wgs Gain Loss On Debt Forgiveness
GainLossOnDebtForgiveness
2750000 usd
wgs Gain Loss On Debt Forgiveness
GainLossOnDebtForgiveness
0 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-685000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-54350000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-515000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-49176000 usd
us-gaap Inventory Write Down
InventoryWriteDown
3634000 usd
us-gaap Inventory Write Down
InventoryWriteDown
732000 usd
wgs Third Party Payor Reserve Release
ThirdPartyPayorReserveRelease
6848000 usd
wgs Third Party Payor Reserve Release
ThirdPartyPayorReserveRelease
0 usd
wgs Noncash Lease Expense
NoncashLeaseExpense
684000 usd
wgs Noncash Lease Expense
NoncashLeaseExpense
1112000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
387000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
387000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10726000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5491000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-682000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5239000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-39913000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
28557000 usd
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
1371000 usd
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
8618000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-150289000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-254501000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
12144000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
127004000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2874000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4990000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3887000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
43935000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
16665000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 usd
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
461000 usd
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
6494000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-38862000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-138488000 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 usd
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
197659000 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
143002000 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2133000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2632000 usd
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
2000000 usd
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
266000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2223000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
139135000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
197250000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-50016000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-195739000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
138303000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
401469000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88287000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
205730000 usd
us-gaap Interest Paid Net
InterestPaidNet
1116000 usd
us-gaap Interest Paid Net
InterestPaidNet
1795000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
1178000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
487000 usd
us-gaap Stock Issued1
StockIssued1
0 usd
us-gaap Stock Issued1
StockIssued1
172000000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1220000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1546000 usd
wgs Software Development Costs Incurred But Not Yet Paid
SoftwareDevelopmentCostsIncurredButNotYetPaid
0 usd
wgs Software Development Costs Incurred But Not Yet Paid
SoftwareDevelopmentCostsIncurredButNotYetPaid
448000 usd
us-gaap Nature Of Operations
NatureOfOperations
Organization and Description of Business <div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GeneDx Holdings Corp., through its subsidiaries GeneDx, LLC and Sema4 OpCo, Inc., provides genomics-related diagnostic and information services and pursues genomics medical research. GeneDx utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process DNA-containing samples, analyzes information about patient-specific genetic variation and generates test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings’ operating subsidiaries primarily serve healthcare professionals who work with their patients and bills third-party payors across the United States.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2023, Sema4 Holdings Corp. changed its name to GeneDx Holdings Corp. The Company’s Class A common stock and public warrants are listed on the Nasdaq under the symbols “WGS” and “WGSWW,” respectively. </span></div><div style="margin-bottom:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">herein or unless the context otherwise requires, references in these notes to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">“GeneDx Holdings” refer to GeneDx Holdings Corp., a Delaware corporation (f/k/a Sema4 Holdings Corp. (“Sema4 Holdings”));</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">“Legacy GeneDx” refer to GeneDx, LLC, a Delaware limited liability company (formerly, GeneDx, Inc., a New Jersey corporation), which we acquired on April 29, 2022 (the “Acquisition”);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">“Legacy Sema4” refer to Mount Sinai Genomics, Inc. d/b/a as Sema4, a Delaware corporation, which consummated the business combination with CM Life Sciences, Inc. (“CMLS”) on July 22, 2021 (the “Business Combination”); and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">“we,” “us” and “our,” the “Company” and “GeneDx” refer, as the context requires, to:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Legacy Sema4 prior to the Business Combination, and GeneDx Holdings and its consolidated subsidiaries following the consummation of the Business Combination; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Legacy GeneDx prior to the Acquisition, and GeneDx Holdings and its consolidated subsidiaries following the consummation of the Acquisition.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">“Company,” or “GeneDx” refer to (i) Legacy Sema4 prior to the consummation of the Business Combination; and (ii) GeneDx Holdings and its subsidiaries following the consummation of the Business Combination (including, following the consummation of the Acquisition, Legacy GeneDx).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging Growth Company</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012. As such, the Company is eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including reduced reporting and extended transition periods to comply with new or revised accounting standards for public business entities. The Company has elected to avail itself of this exemption and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will remain an emerging growth company until the earliest of (1) December 31, 2025, (2) the last day of the fiscal year in which total annual gross revenue are at least $1.235 billion, (3) the last day of the fiscal year in which the Company is deemed to be a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which would occur if the market value of our Class A common stock held by non-affiliates exceeded $700.0 million at the last business day of the second fiscal quarter of such year or (4) the date on which the Company has issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</span></div>
CY2023Q3 wgs Class Of Warrant Or Right Target Share Price Of Warrants Or Rights For Redemption
ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption
594.00
wgs Redemption Price Per Warrant
RedemptionPricePerWarrant
0.33
wgs Number Of Days For Written Notice Of Redemption
NumberOfDaysForWrittenNoticeOfRedemption
30 day
wgs Common Stock Threshold Trading Days
CommonStockThresholdTradingDays
30 day
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. The Company bases these estimates on current facts, historical and anticipated results, trends and various other assumptions that it believes are reasonable in the circumstances, including assumptions as to future events. These estimates include, but are not limited to, the transaction price for certain contracts with customers, potential or actual claims for recoupment from third-party payors, the capitalization of software costs, the valuation of stock-based awards, inventory, earn-out contingent liabilities and earn-out Restricted Stock Units (“RSUs”). Actual results could differ materially from those estimates, judgments and assumptions.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses both the self-pay patient and, if applicable, the third-party payor that reimburses the Company on the patient’s behalf when evaluating the concentration of credit risk. Significant patients and payors are those that represent more than 10% of the Company’s total revenues for the period or accounts receivable balance at each respective balance sheet date. The significant concentrations of accounts receivable at September 30, 2023 and December 31, 2022 were primarily from managed care insurance companies, institutional billed accounts, and data arrangements. There was no individual patient or client that accounted for 10% or more of the Company’s revenue or accounts receivable for any of the periods presented. The Company does not require collateral as a means to mitigate patient or payor credit risk.</span></div>
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
666516 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
666515 shares
CY2023Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
53303000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
83234000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
145148000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
173344000 usd
CY2023Q3 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
3000000 usd
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
-30100000 usd
CY2021 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
-24200000 usd
CY2023Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
3900000 usd
CY2023Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P2Y
CY2023Q3 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
400000 usd
CY2022Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
300000 usd
CY2023Q3 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
400000 usd
CY2022Q3 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
500000 usd
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
1500000 usd
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
1500000 usd
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
114300000 usd
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
26900000 usd
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
123900000 usd
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
0 usd
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
0 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-10200000 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
139724000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
152987000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
103978000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
101460000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
35746000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51527000 usd
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5200000 usd
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7000000.0 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17100000 usd
CY2023Q3 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
200000 usd
CY2022Q3 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
1700000 usd
us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
5900000 usd
us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
5000000.0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
3000000 usd
CY2023Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P23Y
CY2023Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P13Y
wgs Payment For Early Termination Fees
PaymentForEarlyTerminationFees
8400000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
2000000 usd
wgs Increase Decrease In Financing Lease Liabilities
IncreaseDecreaseInFinancingLeaseLiabilities
2600000 usd
CY2023Q3 us-gaap Impairment Of Leasehold
ImpairmentOfLeasehold
8300000 usd
us-gaap Impairment Of Leasehold
ImpairmentOfLeasehold
9900000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19425000 usd
CY2017Q2 wgs Related Party Transaction Funding Commitment To Be Received Maximum
RelatedPartyTransactionFundingCommitmentToBeReceivedMaximum
55000000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
497000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1211000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
1234000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
1260000 usd
CY2023Q3 wgs Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
2048000 usd
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
6250000 usd
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
198000 usd
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6052000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
196000000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
19869000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
176131000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
431000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1273000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
586000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
41553000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-500000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-49100000 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0035
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0005
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-42286000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-77581000 usd
us-gaap Net Income Loss
NetIncomeLoss
-149994000 usd
us-gaap Net Income Loss
NetIncomeLoss
-240219000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25788747 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25788747 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11538308 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11538308 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23777327 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23777327 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9741250 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9741250 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.64
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.64
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.72
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-24.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-24.66
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2987526 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2942875 shares
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
5023000 usd
us-gaap Restructuring Charges
RestructuringCharges
4548000 usd
us-gaap Payments For Restructuring
PaymentsForRestructuring
8081000 usd
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
1490000 usd
CY2022Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
500 position
CY2022Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Inception To Date Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent
0.325
CY2023Q3 us-gaap Restructuring Costs
RestructuringCosts
2191000 usd
CY2022Q3 us-gaap Restructuring Costs
RestructuringCosts
8992000 usd
us-gaap Restructuring Costs
RestructuringCosts
4548000 usd
us-gaap Restructuring Costs
RestructuringCosts
18554000 usd
CY2023Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
50 position
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87387000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
123933000 usd
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
900000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
14370000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88287000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
138303000 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10737000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
11822000 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
5024000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
6390000 usd
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 usd
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
13470000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15761000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
31682000 usd
CY2023Q3 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
5159000 usd
CY2022Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
6485000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
900000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
900000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6059000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7385000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
15373000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
46017000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13322000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20314000 usd
CY2023Q3 wgs Third Party Payor Reserve Current
ThirdPartyPayorReserveCurrent
10153000 usd
CY2022Q4 wgs Third Party Payor Reserve Current
ThirdPartyPayorReserveCurrent
17001000 usd
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
25000 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1546000 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
38873000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
84878000 usd
CY2023Q3 wgs Warrant Liability
WarrantLiability
660000 usd
CY2022Q4 wgs Warrant Liability
WarrantLiability
418000 usd
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
0 usd
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1600000 usd
CY2023Q3 wgs Third Party Payor Reserve Non Current
ThirdPartyPayorReserveNonCurrent
22000000 usd
CY2022Q4 wgs Third Party Payor Reserve Non Current
ThirdPartyPayorReserveNonCurrent
22000000 usd
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22660000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
24018000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
53303000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
83234000 usd
CY2023Q3 wgs Adjusted Cost Of Good Sold
AdjustedCostOfGoodSold
26304000 usd
CY2022Q3 wgs Adjusted Cost Of Good Sold
AdjustedCostOfGoodSold
61508000 usd
CY2023Q3 wgs Adjusted Gross Margin
AdjustedGrossMargin
26999000 usd
CY2022Q3 wgs Adjusted Gross Margin
AdjustedGrossMargin
21726000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
25259000 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
13549000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
145148000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
173344000 usd
wgs Adjusted Cost Of Good Sold
AdjustedCostOfGoodSold
83662000 usd
wgs Adjusted Cost Of Good Sold
AdjustedCostOfGoodSold
165957000 usd
wgs Adjusted Gross Margin
AdjustedGrossMargin
61486000 usd
wgs Adjusted Gross Margin
AdjustedGrossMargin
7387000 usd
us-gaap Gross Profit
GrossProfit
59252000 usd
us-gaap Gross Profit
GrossProfit
-10424000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
wgs-20230930_cal.xml Edgar Link unprocessable
0001818331-23-000068-index-headers.html Edgar Link pending
0001818331-23-000068-index.html Edgar Link pending
0001818331-23-000068.txt Edgar Link pending
0001818331-23-000068-xbrl.zip Edgar Link pending
ceocertificationfor-ex311x.htm Edgar Link pending
ceocertificationfor-ex321x.htm Edgar Link pending
cfocertificationfor-ex312x.htm Edgar Link pending
cfocertificationfor-ex322x.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
wgs-20230930.htm Edgar Link pending
wgs-20230930.xsd Edgar Link pending
wgs-20230930_g1.jpg Edgar Link pending
wgs-20230930_def.xml Edgar Link unprocessable
wgs-20230930_lab.xml Edgar Link unprocessable
wgs-20230930_pre.xml Edgar Link unprocessable
wgs-20230930_htm.xml Edgar Link completed